Trinity Biotech (TRIB) Non-Current Receivables (2016 - 2025)
Historic Non-Current Receivables for Trinity Biotech (TRIB) over the last 17 years, with Q2 2025 value amounting to $10.9 million.
- Trinity Biotech's Non-Current Receivables fell 3765.1% to $10.9 million in Q2 2025 from the same period last year, while for Jun 2025 it was $10.9 million, marking a year-over-year decrease of 3765.1%. This contributed to the annual value of $16.1 million for FY2024, which is 1556.72% up from last year.
- Per Trinity Biotech's latest filing, its Non-Current Receivables stood at $10.9 million for Q2 2025, which was down 3765.1% from $16.1 million recorded in Q4 2024.
- Trinity Biotech's Non-Current Receivables' 5-year high stood at $21.2 million during Q3 2024, with a 5-year trough of $10.9 million in Q2 2025.
- For the 5-year period, Trinity Biotech's Non-Current Receivables averaged around $15.8 million, with its median value being $15.9 million (2022).
- Its Non-Current Receivables has fluctuated over the past 5 years, first soared by 4050.35% in 2024, then plummeted by 3765.1% in 2025.
- Trinity Biotech's Non-Current Receivables (Quarter) stood at $16.1 million in 2021, then decreased by 2.25% to $15.8 million in 2022, then fell by 11.76% to $13.9 million in 2023, then grew by 15.57% to $16.1 million in 2024, then crashed by 32.19% to $10.9 million in 2025.
- Its Non-Current Receivables was $10.9 million in Q2 2025, compared to $16.1 million in Q4 2024 and $21.2 million in Q3 2024.